Clinipace Reports Positive Results for 2013 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Clinipace Reports Positive Results for 2013

Source: Applied Clinical Trials

Clinipace Worldwide, the CRO headquartered in Research Triangle Park, North Carolina, has announced that 2013 was its strongest year to date. New clinical development projects and regulatory and strategic development engagements accounted for 114% growth in bookings compared to 2012, according to the company.

Clinipace reported 63% growth in consolidated revenues, plus 194% year-on-year growth in new bookings for full-service studies and a tripling of average contract value. It experienced solid growth in several therapeutic areas, including oncology/hematology, infectious disease, gastroenterology, cardiovascular, nephrology, immunology, pediatrics, and women’s health. One of the company’s areas of specialty is managing oncology clinical trials.

The firm hired 50 net new team members in 2013, and expects to expand by an additional 25% in 2014, especially in clinical monitoring, site management services, clinical project management, clinical data management, and financial operations.
Outside of the U.S., the CRO’s offices are located in Zurich (Switzerland), Munich (Germany), High Wycombe (U.K.), Tel-Aviv (Israel), Sao Paulo (Brazil), Buenos Aires (Argentina), and Trivandrum Kerala and New Delhi (India). 

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here